1
Clinical Trials associated with Novel oral poliomyelitis vaccine type 3(nOPV3)(PATH) / Not yet recruitingPhase 1/2IIT A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Age De-escalation, Dose Combination Ranging Study to Assess the Safety and Immunogenicity of Co-administered Novel Live Attenuated Trivalent Oral Poliomyelitis Vaccine in Healthy Adults, Young Children, and Neonates and Co-administered Novel Live Attenuated Monovalent Oral Poliomyelitis Vaccines 1 and 2 in Neonates in Bangladesh
The main objectives of this study are to :
* evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines;
* evaluate the safety and tolerability of combined novel oral poliovirus vaccine type 1 (nOPV1) + novel oral poliovirus vaccine type 2 (nOPV2) in neonates, relative to those receiving the bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) control.
* compare type-specific cumulative seroconversion rates of poliovirus neutralizing antibody (NAb) titers, among all tnOPV dose combinations, following 4 vaccinations in healthy neonates;
* evaluate the type-specific cumulative seroconversion rate of poliovirus NAb titers among healthy neonates following 4 doses of combined nOPV1+nOPV2.
100 Clinical Results associated with Novel oral poliomyelitis vaccine type 3(nOPV3)(PATH)
100 Translational Medicine associated with Novel oral poliomyelitis vaccine type 3(nOPV3)(PATH)
100 Patents (Medical) associated with Novel oral poliomyelitis vaccine type 3(nOPV3)(PATH)
100 Deals associated with Novel oral poliomyelitis vaccine type 3(nOPV3)(PATH)